UCB SA (OTCMKTS:UCBJY) Short Interest Up 166.7% in May

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 3,200 shares, a growth of 166.7% from the April 30th total of 1,200 shares. Based on an average daily volume of 158,300 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

UCB Price Performance

UCBJY traded down $2.40 on Tuesday, reaching $90.68. The company had a trading volume of 67,519 shares, compared to its average volume of 48,050. The business has a 50 day simple moving average of $85.88 and a 200 day simple moving average of $93.13. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. UCB has a 52-week low of $69.12 and a 52-week high of $106.60.

UCB Increases Dividend

The business also recently announced a dividend, which was paid on Wednesday, May 14th. Investors of record on Tuesday, April 29th were paid a $0.4838 dividend. This is an increase from UCB's previous dividend of $0.46. This represents a yield of 0.62%. The ex-dividend date of this dividend was Monday, April 28th.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.